PEGylation of 99mTc-labeled bombesin analogues improves their pharmacokinetic properties

Nuclear Medicine and Biology

Volumn 38, Issue 7, 2011, Pages 997-1009

  Däpp, Simone ^a   Garayoa, Elisa García ^a   Maes, Veronique ^b   Brans, Luc ^b   Tourwé, Dirk A ^b   Müller, Cristina ^a   Schibli, Roger ^a,c  

^a ETH Zurich   (Switzerland)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c ETH ZURICH   (Switzerland)

Author keywords

Bombesin; Gastrin releasing peptide receptor; PEGylation; Prostate cancer; SPECT CT imaging; Technetium 99m

Indexed keywords

BOMBESIN DERIVATIVE; BOMBESIN RECEPTOR; GASTRIN RELEASING PEPTIDE; MACROGOL; PEGYLATED LYSINE BOMBESIN CONJUGATE TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL INTERACTION; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG SCREENING; DRUG STABILITY; DRUG UPTAKE; ENZYMATIC DEGRADATION; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PLASMA CLEARANCE; PROSTATE CARCINOMA; PROTEIN SYNTHESIS; RADIOACTIVITY; RADIOLOGICAL PARAMETERS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEADY STATE; TIME SERIES ANALYSIS; TUMOR XENOGRAFT; URINARY EXCRETION;

AMINO ACID SEQUENCE; ANIMALS; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYSINE; MALE; MICE; MOLECULAR WEIGHT; OCTANOLS; ORGANOTECHNETIUM COMPOUNDS; PHOSPHATES; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, BOMBESIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053587664     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.014     Document Type: Article

References (48)

1. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
2. Nagalla S.R., Barry B.J., Falick A.M., Gibson B.W., Taylor J.E., Dong J.Z., et al. There are three distinct forms of bombesin - identification of [Leu13]bombesin, [Phe13]bombesin, and [Ser3,Arg10,Phe13]bombesin in the frog Bombina orientalis. J Biol Chem 1996, 271:7731-7737.
3. Reubi J.C., Wenger S., Schmuckli-Maurer J., Schaer J.C., Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-Tyr6, beta-Ala11, Phe13, Nle14] bombesin(6-14). Clin Cancer Res 2002, 8:1139-1146.
4. Gugger M., Reubi J.C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999, 155:2067-2076.
5. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
6. Moody T.W., Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 1993, 52:1161-1173.
7. Zhou J., Chen J., Mokotoff M., Zhong R., Shultz L.D., Ball E.D. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res 2003, 9:4953-4960.
8. Hoffman T.J., Gali H., Smith C.J., Sieckman G.L., Hayes D.L., Owen N.K., et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44:823-831.
9. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64:6707-6715.
10. Schroeder R.P., Müller C., Reneman S., Melis M.L., Breeman W.A., de Blois E., et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 2010, 37:1386-1396.
11. Smith C.J., Volkert W.A., Hoffman T.J. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 2003, 30:861-868.
12. Nock B., Nikolopoulou A., Chiotellis E., Loudos G., Maintas D., Reubi J.C., et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003, 30:247-258.
13. Nock B.A., Nikolopoulou A., Galanis A., Cordopatis P., Waser B., Reubi J.C., et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 2005, 48:100-110.
14. Garcia Garayoa E., Schweinsberg C., Maes V., Brans L., Bläuenstein P., Tourwe D.A., et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem 2008, 19:2409-2416.
15. Schweinsberg C., Maes V., Brans L., Bläuenstein P., Tourwe D.A., Schubiger P.A., et al. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem 2008, 19:2432-2439.
16. Zhang H., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007, 34:1198-1208.
17. Lantry L.E., Cappelletti E., Maddalena M.E., Fox J.S., Feng W., Chen J., et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006, 47:1144-1152.
18. Garrison J.C., Rold T.L., Sieckman G.L., Naz F., Sublett S.V., Figueroa S.D., et al. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model. Bioconjug Chem 2008, 19:1803-1812.
19. Mansi R., Wang X., Forrer F., Kneifel S., Tamma M.L., Waser B., et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009, 15:5240-5249.
20. Smith C.J., Gali H., Sieckman G.L., Higginbotham C., Volkert W.A., Hoffman T.J. Radiochemical investigations of 99mTc-N3S-X-BBN[7-14]NH2: an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 2002, 14:93-102.
21. Kunstler J.U., Veerendra B., Figueroa S.D., Sieckman G.L., Rold T.L., Hoffman T.J., et al. Organometallic Tc-99m(III) '4+1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem 2007, 18:1651-1661.
22. Prasanphanich A.F., Nanda P.K., Rold T.L., Ma L.X., Lewis M.R., Garrison J.C., et al. [Cu-64-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007, 104:12462-12467.
23. Garcia Garayoa E., Ruegg D., Bläuenstein P., Zwimpfer M., Khan I.U., Maes V., et al. Chemical and biological characterization of new Re(CO)3/99mTc(CO)3 bombesin analogues. Nucl Med Biol 2007, 34:17-28.
24. Liu S., Edwards D.S. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999, 99:2235-2268.
25. Alves S., Correia J.D., Santos I., Veerendra B., Sieckman G.L., Hoffman T.J., et al. Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M(CO)3]+ moiety. Nucl Med Biol 2006, 33:625-634.
26. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-326.
27. Abd-Elgaliel W.R., Gallazzi F., Garrison J.C., Rold T.L., Sieckman G.L., Figueroa S.D., et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem 2008, 19:2040-2048.
28. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-1277.
29. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994, 83:601-606.
30. Lee L.S., Conover C., Shi C., Whitlow M., Filpula D. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 1999, 10:973-981.
31. Knauf M.J., Bell D.P., Hirtzer P., Luo Z.P., Young J.D., Katre N.V. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 1988, 263:15064-15070.
32. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
33. Chen X., Park R., Hou Y., Khankaldyyan V., Gonzales-Gomez I., Tohme M., et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004, 31:1081-1089.
34. Lee H., Jang I.H., Ryu S.H., Park T.G. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res 2003, 20:818-825.
35. Tsunoda S., Ishikawa T., Watanabe M., Kamada H., Yamamoto Y., Tsutsumi Y., et al. Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent. Br J Haematol 2001, 112:181-188.
36. Werle M., Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006, 30:351-367.
37. Fee C.J. Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules. Biotechnol Bioeng 2007, 98:725-731.
38. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006, 45:1198-1215.
39. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
40. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10:1451-1458.
41. La Bella R., Garcia-Garayoa E., Bahler M., Blauenstein P., Schibli R., Conrath P., et al. A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem 2002, 13:599-604.
42. Schibli R., La Bella R., Alberto R., Garcia-Garayoa E., Ortner K., Abram U., et al. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of 99mTc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjug Chem 2000, 11:345-351.
43. Pillarsetty N., Cai S., Ageyeva L., Finn R.D., Blasberg R.G. Synthesis and evaluation of [18F] labeled pyrimidine nucleosides for positron emission tomography imaging of herpes simplex virus 1 thymidine kinase gene expression. J Med Chem 2006, 49:5377-5381.
44. Bauer R., Pabst H.W. Tc-generators - yield of 99mTc and ratio to 'inactive' 99Tc. Eur J Nucl Med 1982, 7:35-36.
45. Chen X., Hou Y., Tohme M., Park R., Khankaldyyan V., Gonzales-Gomez I., et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 2004, 45:1776-1783.
46. Chen X., Sievers E., Hou Y., Park R., Tohme M., Bart R., et al. Integrin αvβ3-targeted imaging of lung cancer. Neoplasia 2005, 7:271-279.
47. Kubetzko S., Sarkar C.A., Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005, 68:1439-1454.
48. Nakaoka R., Tabata Y., Yamaoka T., Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 1997, 46:253-261.